MORRISVILLE, N.C., July 21, 2015 (GLOBE NEWSWIRE) -- nContact, a leader in the development of Arrhythmia and Cardiovascular Disease Management Programs, announced that William (Bill) Hawkins has been appointed as Chairman of its Board of Directors.
Bill Hawkins has served as a special advisor to the nContact Board since 2013 and is a veteran entrepreneur and executive in the medical device arena, with more than 20 years of C-Suite experience in cardiology, surgery, and vascular therapies. From 2002 to 2011, Bill was CEO and Chairman of the Board of Medtronic, Inc., a global leader in cardiac electrophysiology devices and programs. Most recently, Bill was President and CEO of Immucor, a leader in the advancement of transfusion and transplantation diagnostics. Bill previously held executive leadership roles in several global medical device companies, including Novoste Corporation, Ethicon Endosurgery/Johnson & Johnson, Devices for Vascular Intervention/Guidant Corporation, and IVAC Corporation/Eli Lilly.
“We are pleased to have Bill leading our Board of Directors at this exciting time in the Company’s evolution,” stated Jay Brumfield, CEO of nContact. “Bill’s track record in accelerating growth for emerging cardiovascular businesses and technologies will be of important value to nContact and to the large population of longtime arrhythmia patients looking for new options.”
The multidisciplinary Convergent Procedure is performed in a single setting in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2-cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions are created by an electrophysiologist, using specialized mapping and diagnostics to ensure a comprehensive approach.
About nContact, Inc.
nContact’s mission is to transform the underserved arrhythmia market through the advancement of less invasive ablation alternatives for cardiac arrhythmias. The Company is conducting the CONVERGE IDE Clinical Trial, the first head-to-head study to evaluate the Convergent Procedure to catheter ablation in persistent atrial fibrillation (AF) patients. The Company’s lead technology, EPi-Sense® Coagulation System with VisiTrax®, has CE Mark approval in Europe for the coagulation of cardiac tissue in the treatment of atrial fibrillation and atrial flutter. The EPi-Sense Coagulation System with VisiTrax is indicated for endoscopic coagulation of cardiac tissue in the U.S. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, USA. For more information, visit www.ncontactinc.com.
Media Contact: Kris McCulloch nContact, Inc. T (919) 655-1351 email@example.com
Source: nContact, Inc.